Vnitr Lek 2026, 72(2):76-80 | DOI: 10.36290/vnl.2026.017

Novel therapies for hypertrophic cardiomyopathy

Michael Jenąovský, Veronika Puchnerová, Jiří Bonaventura, Petr Oą»ádal
Kardiologická klinika 2. LF UK a FN Motol a Homolka, Praha

Hypertrophic cardiomyopathy (HCM) is a genetic disease that requires complex diagnostics and evolving therapeutic options. We present advances in pharmacotherapy of HCM in the year 2025. We focus on the results of trials involving myosin inhibitors and the implications of these studies on daily practice. Additionally, we explore experimental therapies with novel mechanisms of action in different stages of development. Lastly, we describe the current structure of expert centers that care for HCM patients in the Czech Republic.

Keywords: hypertrophic cardiomyopathy, myosin inhibitors, mavacamten, aficamten.

Accepted: March 25, 2026; Published: April 8, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jenąovský M, Puchnerová V, Bonaventura J, Oą»ádal P. Novel therapies for hypertrophic cardiomyopathy. Vnitr Lek. 2026;72(2):76-80. doi: 10.36290/vnl.2026.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2020;396(10253):759-69. Available from: https://www.thelancet.com/action/showFullText?pii=S014067362031792X Go to original source...
    2. Desai MY, Owens A, Wolski K, et al. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. JAMA Cardiol. 2023;8(10):968-7. Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050 Go to original source...
    3. Garcia-Pavia P, Oręziak A, Masri A, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024;45(47):5071-83. Available from: https://dx.doi.org/10.1093/eurheartj/ehae579 Go to original source... Go to PubMed...
    4. Desai MY, Owens AT, Abraham T, et al. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. New England Journal of Medicine. 2025;393(10):961-72. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2505927 Go to original source...
    5. Desai MY, Olivotto I, Abraham T, et al. Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial. JACC. 2025;86(24):2418-33. Go to original source...
    6. Maron MS, Masri A, Nassif ME, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. NEJM. 2024;390(20):1849-61. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2401424. Go to original source...
    7. Saberi S, Abraham TP, Choudhury L, et al. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. JACC Heart Fail. 2025;13(8). Available from: https://www.jacc.org/doi/10.1016/j.jchf.2025. 03. 040.
    8. Weiner S, Liang L, Masri A, et al. Abstract 4368742: Long-term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM. Circulation. 2025;152(Suppl_3). Available from: https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4368742. Go to original source...
    9. Maron MS, Gimeno JR, Veselka J, et al. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. Eur Heart J. 2025;46(40):4076-86. Available from: https://dx.doi.org/10.1093/eurheartj/ehaf364. Go to original source... Go to PubMed...
    10. Garcia-Pavia P, Maron MS, Masri A, et al. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. NEJM. 2025;393(10):949-60. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2504654. Go to original source...
    11. Cytokinetics, Incorporated - Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy. [cited 2025 Dec 28]. Available from: https://ir.cytokinetics.com/press-releases/press-release-details/2025/Cytokinetics-Announces-Positive-CHMP-Opinion-of-MYQORZO-Aficamten-for-the-Treatment-of-Obstructive-Hypertrophic-Cardiomyopathy/default.aspx.
    12. FDA approves drug to improve functional capacity and symptoms in adults with rare inherited heart condition | FDA. [cited 2025 Dec 28]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-improve-functional-capacity-and-symptoms-adults-rare-inherited-heart-condition.
    13. Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM). [cited 2025 Dec 28]. Available from: https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-positive-top-line-results-from-phase-2-cirrus-hcm-four-week-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-302417857.html.
    14. Maron MS, Mahmod M, Abd Samat AH, et al. Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024;83(21):2037-48. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2024. 03. 387. Go to original source...
    15. Desai MY, Nagueh SF, Giudicessi JR, et al. First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1. Cardiovasc Res. 2025;121(17):2628-31. Available from: https://dx.doi.org/10.1093/cvr/cvaf200. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.